Trial Profile
A Dose Block-randomized, Double-blind, Single Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of HM11260C After Subcutaneous Administration in Healthy Male Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Apr 2014
Price :
$35
*
At a glance
- Drugs Efpeglenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Hanmi Pharmaceutical
- 30 Mar 2010 New trial record